The experts evaluated promising combination of optical and pharmaceutical treatments
BANGKOK – 2 Nov. 2022 – HOYA Vision Care, a leader in optical technology innovation, today announced the outcome of a recently hosted virtual advisory meeting where five well-known experts in pediatric myopia discussed their opinions on combination treatment with atropine and optical inventions for myopia management. The advisory group, composed of key experts from Europe and Asia, including Prof. Hakan Kaymak, Internationale Innovative Ophthalmochirurgie, Duesseldorf, Germany, shared insights based on their clinical experience and research.
“The experts in the advisory meeting agreed that in order to prevent vision complications later in life, early detection, proper diagnostic measurement and treatment of myopia in children is critical,” said Pascal Blaser, Global Medical Affairs Manager Myopia at HOYA Vision Care. “We were pleased to be able to bring together this group of experts to facilitate discussions on the latest treatment options including the combination of optical and pharmaceutical treatments.”
The experts shared and discussed their experience with the MiYOSMART spectacle lens, including the results of a clinical application of the MiYOSMART spectacle lens in combination with 0.01% atropine drops in European myopic children and adolescents when the expected goal using the spectacle lens was not achieved.1 The experts noted a better control effect with the combination treatment. They reported no significant changes in visual acuity or binocular vision between the use of MiYOSMART spectacle lenses alone or in combination with low dosage atropine.
These data shared by the experts, were recently presented at the International Myopia Conference held in Rotterdam, The Netherlands, along with research presented by Prof. Kaymak on his study of axial length growth under treatment with MiYOSMART spectacle lenses and atropine.
A key outcome of the advisory meeting was the group reaching consensus on the use of the combination treatment combining HOYA’s MiYOSMART spectacle lenses and atropine drops for myopia management in children.
“The promising early treatment intervention I have seen in my work combining the MiYOSMART spectacle lens and atropine drops is a very exciting development as we continue to seek an evidence-based approach to myopia management in children,” said Prof. Kaymak, advisory member. “The consensus reached at HOYA’s advisory meeting on the combination treatment protocol helps eye care professionals make informed decisions in addressing the growing global challenge of myopia.”
Since its launch in 2018, MiYOSMART is available in more than 28 markets with over two million spectacle lenses purchased by parents around the world.2
PRODUCT DISCLAIMER – MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.
1 Kaymak H, Lembo A, Lam CSY. HOYA Vision Care Myopia Symposium " New Insights to Advance Myopia Management": Axial length growth under therapy with MiYOSMART spectacle lenses; A comparison of myopia control in European children with Defocus Incorporated Multiple Segments (DIMS) spectacles, atropine, and combined DIMS/atropine; Myopia control effect is influenced by baseline relative peripheral refraction in children wearing Defocus Incorporated Multiple Segments (DIMS) spectacle lenses. International Myopia Conference (IMC) 2022, September 4, Rotterdam, The Netherlands.
2 Based on number of MiYOSMART lenses sold per Hoya sales data on file as of June 2022.
